John has served as a marketing and sales leader for Johnson & Johnson as well as McNeil Consumer & Specialty Pharmaceuticals, the makers of Tylenol, and Lifescan on the OneTouch Glucose Monitor brand, and has a deep-seated understanding of creating value and changing the perspective of consumers from these roles. John received both his B.S. in Accountancy and studied for his M.B.A. at Villanova University.

Gerry's creative talent, OTC industry knowledge, and consumer understanding have been key to his success in bringing new products and technologies to the consumer healthcare market. His background in the regulated pharmaceutical industry combined with his experience in consumer healthcare and patient-centric drug development provides a unique perspective. With more than 25 years of experience as an R&D leader in the consumer healthcare industry, Gerry is acutely aware of the roles that leadership and the R&D function have in driving innovation and growth.

During his tenure at McNeil Consumer Healthcare and Johnson & Johnson, Gerry was instrumental in leading the development of numerous innovative and highly successful products and launching multiple novel drug delivery technologies.

Innovations that have made a real difference for patients and consumers include various taste-masking technologies for pediatric and adult products, unique formulations for combination products such as Imodium® Multi-Symptom Relief, and Pepcid® Complete and novel formats such as Tylenol® Rapid Release Gels that have stood the test of time in the marketplace.

Gerry’s career history also includes having a leadership role in several very successful Rx to OTC switches such as Pepcid® AC and Zyrtec®.

His diverse industry experience includes areas such as specialty chemicals, large OTC joint venture partnerships, specialty pharmaceuticals, OTC, and nutritional products which give him a broad perspective on technology in the consumer healthcare industry.

Gerry earned his Ph.D. and BSc Hons. in Chemistry from University College Dublin, Ireland. He holds over 30 patents in the field of drug delivery/pharmaceutical formulation, has authored several papers, and delivered presentations at industry conferences.

As Chief Medical Officer for multiple companies including Adamas, Aquinox, Crescendo Bioscience, Schiff Nutrition, and SetPoint Medical, David has played pivotal roles in moving early-stage R&D programs successfully through clinical development and product commercialization and evaluating a broad range of in-licensing opportunities. He has a keen interest in anti-inflammatory science.

David is a graduate of Yale University as well as the New York University Grossman School of Medicine.